Lyra Health vs Danaher Corporation

Side-by-side comparison of AI visibility scores, market position, and capabilities

Danaher Corporation leads in AI visibility (92 vs 68)
Lyra Health logo

Lyra Health

ChallengerHealthcare Tech

Mental Health Benefits & Digital Therapeutics

Leading mental health benefits platform for employers. Founded 2015 by ex-Facebook CFO. $5.58B valuation, $915M total funding. Serves 20M+ people through employer contracts.

AI VisibilityBeta
Overall Score
B68
Category Rank
#1 of 1
AI Consensus
54%
Trend
up
Per Platform
ChatGPT
61
Perplexity
78
Gemini
75

About

Lyra Health is a workforce mental health platform founded in 2015 by David Ebersman (former CFO of Facebook/Meta) and Dena Bravata, headquartered in Burlingame, California. It provides AI-powered mental health benefits to employers through therapy, coaching, preventive care, specialized programs (substance use, DBT), and the Empower AI platform for personalized support.

Full profile
Danaher Corporation logo

Danaher Corporation

LeaderHealthcare Tech

Enterprise

Washington DC life sciences instruments (NYSE: DHR) at $23.9B FY2024 revenue; Cytiva bioprocessing, Beckman Coulter diagnostics, biopharma destocking recovery, 2025 core revenue +3% guidance competing with Thermo Fisher.

AI VisibilityBeta
Overall Score
A92
Category Rank
#17 of 290
AI Consensus
60%
Trend
stable
Per Platform
ChatGPT
96
Perplexity
91
Gemini
85

About

Danaher Corporation is a Washington, D.C.-based global science and technology company — publicly traded on the New York Stock Exchange (NYSE: DHR) as an S&P 500 Health Care component — developing, manufacturing, and marketing analytical instruments, reagents, consumables, software, and services for life sciences research, clinical diagnostics, and environmental monitoring through approximately 65,000 employees worldwide. In fiscal year 2024, Danaher reported revenues of $23.9 billion (flat year-over-year) with non-GAAP core revenue declining 1% as the biopharma sector's inventory destocking cycle continued, with Q4 2024 revenue of $6.5 billion (+2.0% reported, +1.0% core) representing an inflection toward recovery, generating $6.7 billion in operating cash flow and $5.3 billion in free cash flow. Danaher guided 2025 core revenue growth of approximately 3% — marking the expected return to growth as biopharma customers who destocked pandemic-era bioprocessing supply surpluses return to normalized purchasing. CEO Rainer Blair leads Danaher's post-spinoff strategy: in September 2023, Danaher separated its Environmental & Applied Solutions segment as Veralto Corporation (NYSE: VLTO), creating two independent public companies — Danaher (pure-play life sciences and diagnostics) and Veralto (water quality and product identification). Danaher's current portfolio centers on bioprocessing (Cytiva's bioreactors, membranes, single-use manufacturing for drug production), clinical diagnostics (Beckman Coulter chemistry and hematology analyzers, Radiometer blood gas analyzers, Cepheid molecular diagnostics), and life sciences research instruments (SCIEX mass spectrometry, Leica Microsystems microscopy).

Full profile

AI Visibility Head-to-Head

68
Overall Score
92
#1
Category Rank
#17
54
AI Consensus
60
up
Trend
stable
61
ChatGPT
96
78
Perplexity
91
75
Gemini
85
63
Claude
98
74
Grok
83

Key Details

Category
Mental Health Benefits & Digital Therapeutics
Enterprise
Tier
Challenger
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Lyra Health
Mental Health Benefits & Digital Therapeutics

Integrations

Only Lyra Health
Danaher Corporation is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.